Evaluation of vitamin D efficacy on biochemical markers

Conditions

Vitamin D Deficiency.

Sharifan P, Darroudi S, Rafiee M, Roustai Geraylow K, Hemmati R, Rashidmayvan M, Safarian M, Eslami S, Vatanparast H, Zare-Feizabadi R, Mohammadi-Bjgiran M, Ghazizadeh H, Khorasanchi Z, Bagherniya M, Ferns G, Rezaie M, Ghayour-Mobarhan M.

2023-09-251 citations

10.1186/s41043-023-00401-6

The efficacy of dairy products fortified with nano-encapsulated vitamin D3 on physical and mental aspects of the health in obese subjects; the protocol of the SUVINA trial

Payam Sharifan, Mohammad Bagherniya, Maryam Mohammadi Bajgiran, Mohammad Safarian, Hassan Vatanparast et al. (16 authors)

Translational Metabolic Syndrome Research2021-02-0711 citations

10.1016/j.tmsr.2021.01.001

Effect of low-fat dairy products fortified with 1500IU nano encapsulated vitamin D<sub>3</sub> on cardiometabolic indicators in adults with abdominal obesity: a total blinded randomized controlled trial

Payam Sharifan, Amirhosein Ziaee, Susan Darroudi, Mitra Rezaie, Mohammad Safarian et al. (16 authors)

Current Medical Research and Opinion2021-01-1416 citations

10.1080/03007995.2021.1874324

Efficacy of low‐fat milk and yogurt fortified with encapsulated vitamin D<sub>3</sub>on improvement in symptoms of insomnia and quality of life: Evidence from the SUVINA trial

Payam Sharifan, Mahdieh Khoshakhlagh, Zahra Khorasanchi, Susan Darroudi, Mitra Rezaie et al. (11 authors)

Food Science & Nutrition2020-07-0623 citations

10.1002/fsn3.1750

Interventions

Intervention 1: First control group: 70 adults receive 200 ml of daily non-fortified milk for 2.5 months. Intervention 2: Intervention group: 70 adults receive 200 ml daily milk fortified with encapsu

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: aged between 18 to 65 having full consent for participation in trial

Exclusion criteria

Exclusion criteria: not taking any vitamin D supplement in the last three months before the trial not having Chronic Liver Diseases, Cystic Fibrosis, Crohn's, and Sprue

Design outcomes

Primary

Measure	Time frame
Bone Density. Timepoint: Baseline, 75th day. Method of measurement: BMD Method.;Anthropometric factors. Timepoint: Baseline, 75th day. Method of measurement: using standard scales for weight and height measurement.;Blood pressure. Timepoint: Baseline, 75th day. Method of measurement: Systolic and diastolic blood pressure measurement.;Depression. Timepoint: Baseline, 75th day. Method of measurement: Beck depression assessment.;Eating habits. Timepoint: baseline. Method of measurement: FFQ.;Biochemical state. Timepoint: Baseline, 75th day. Method of measurement: Blood test.	—

Measure

Time frame

Bone Density. Timepoint: Baseline, 75th day. Method of measurement: BMD Method.;Anthropometric factors. Timepoint: Baseline, 75th day. Method of measurement: using standard scales for weight and height measurement.;Blood pressure. Timepoint: Baseline, 75th day. Method of measurement: Systolic and diastolic blood pressure measurement.;Depression. Timepoint: Baseline, 75th day. Method of measurement: Beck depression assessment.;Eating habits. Timepoint: baseline. Method of measurement: FFQ.;Biochemical state. Timepoint: Baseline, 75th day. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPayam Sharifan

Mashhad University of Medical Sciences

Sharifanp961@mums.ac.ir+98 51 3882 9260

Outcome results

None listed